Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.